Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-06 · accession 0001919170-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-10 | 2026-02-06 | EBS | Glessner Coleen | EVP, Quality, Ethics, CPL | D - Sale to Iss | $10.92 | -28.8K | 115.5K | -20% | -$315.0K | |
| 2026-02-10 | 2026-02-06 | EBS | Glessner Coleen | EVP, Quality, Ethics, CPL | F - Tax | $10.92 | -2,852 | 112.6K | -2% | -$31.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-06 | D | D | 28,847 | $10.92 | 115,472 | D | — | — | (F1) Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 9,615 shares of common stock, which is less than the 38,462 shares previously reported on March 02, 2023 and June 09, 2023. |
| 2 | Common | Common Stock | 2026-02-06 | F | D | 2,852 | $10.92 | 112,620 | D | — | — | (F2) Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units |